3 Sales Growth Stocks to Buy Amid Renewed Middle East Tensions

Zacks highlights Globus Medical, NetApp and Assurant as buys under a screen requiring sales growth above industry levels, more than $500 million in cash flow, favorable price-to-sales ratios, positive sales-estimate revisions, operating margins above 5% and ROE above 5%. Globus Medical is projected to grow 2026 sales by 8.8% and holds a Zacks Rank #1; NetApp is expected to grow fiscal 2027 sales 18.6% and Assurant's 2026 sales are projected to rise 8.5%, with both rated Zacks Rank #2. The article frames these selections as resilient growth opportunities despite macro risks including Fed uncertainty, elevated yields, inflation, tariffs, oil prices and high technology valuations.

Analysis

This is a low-information screen, not a fundamental catalyst: the stated growth figures and ranking methodology are unlikely to change institutional estimates on their own. The useful signal is factor-level—if rates remain elevated and AI leadership broadens, profitable growth at a reasonable revenue multiple can attract incremental flows away from long-duration, unprofitable technology. That favors NTAP most, but only if its AI-related storage demand converts into recurring software/services mix rather than hardware-led revenue with limited operating leverage.

GMED has the cleaner idiosyncratic setup: post-integration execution and procedure-volume leverage matter more than a screen-based sales-growth label. Its key competitive risk is that hospital capital budgets and spine/robotics adoption favor larger installed-base rivals such as MDT and SYK; evidence of sales-force productivity and sustained margin recovery would support multiple expansion over 6-18 months. AIZ is less a revenue-growth compounder than a partner-concentration and loss-ratio story: device-protection attach rates, carrier/client renewals, and housing-related claims severity determine whether revenue growth reaches free cash flow.

Contrarian view: the market may already price NTAP's AI exposure more aggressively than its underlying enterprise-storage cycle warrants. A weaker hyperscaler capex read, delayed on-prem AI deployments, or gross-margin pressure from product mix could reverse the relative trade within one or two quarters. For all three, the screen omits valuation, organic versus acquired growth, and estimate dispersion—the missing data required before treating the recommendation as a durable long signal.

Key Decisions for Investors

• Watch, do not chase the publication: require post-earnings upward FY revenue and EPS revisions plus stable/guided-up gross margin before initiating any position; the article itself is not a tradable catalyst.
• Conditional 3-6 month pair: long GMED / short MDT in equal dollar size after GMED demonstrates continued procedure-led organic growth and integration margin delivery. Thesis fails on a material GMED guidance cut or evidence that MDT/SYK are gaining spine/robotics share; target 10-15% relative return versus roughly 7-8% relative-risk stop.
• Tactical 1-3 month NTAP long only on a pullback or ahead of earnings if enterprise AI/storage backlog and all-flash/software mix are independently confirmed. Cap position size because AI expectations create downside asymmetry; exit on decelerating product revenue or gross-margin guide-down, and use a 8-10% stop.
• Maintain AIZ as a watch item rather than a new long until disclosure clarifies client renewal concentration, device-protection economics, and catastrophe/claims trends. A favorable renewal or lower loss-ratio catalyst could justify a 6-12 month long; adverse claims development would outweigh modest top-line growth.